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WS14.1 Ivacaftor potentiates mutant CFTR forms associated with
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Objectives: Clinical studies have shown that ivacaftor, an oral CFTR potentiator,
increased CFTR channel activity and improved lung function in patients with CF
who have the G551D-CFTR gating mutation. The aim of this in vitro study was to
evaluate whether ivacaftor potentiates mutant CFTR with non-gating CFTR channel
defects.
Methods: The pharmacological action of ivacaftor on over 50 mutant CFTR forms
was evaluated in electrophysiological studies using a panel of Fischer rat thyroid
cells or human bronchial epithelia cells isolated from patients with CF.
Results: Ivacaftor potentiated multiple mutant CFTR forms that deliver sufﬁcient
amounts of functional CFTR to the cell surface to result in residual baseline chloride
transport. These included CFTR mutations that result in mild defects in CFTR
processing and delivery to the cell surface, reduced channel conductance, or reduced
CFTR synthesis. In addition, ivacaftor also potentiated mutant CFTR forms that
result in residual chloride transport due to defects in both channel gating activity
and channel conductance, such as R117H-CFTR. Single-channel studies indicated
that ivacaftor increased the channel open probability of R117H-CFTR to enhance
chloride transport. In contrast, a minimal ivacaftor response was observed in cells
expressing mutant CFTR forms associated with minimal baseline chloride transport.
Conclusions: This in vitro study indicated that ivacaftor acts on multiple mutant
CFTR forms with defects beyond channel gating and supports investigation of the
potential clinical beneﬁt of ivacaftor in patients with CF who have cell surface
CFTR that results in residual chloride transport.
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Pigs share many features of lung biology with humans, including anatomy, elec-
trolyte transport, and immune responses. Models of neonatal CF pigs displayed a
high degree of similarity in electrophysiological and pathological changes to human
neonates with CF. The main objective of this study is to develop a pre-clinical model
for delivery of the CFTR gene. In this study, we used wild-type pigs to investigate
the technique of gene delivery using helper-dependent adenoviral (HD-Ad) vectors.
HD-Ad vectors do not contain any viral coding sequences, and therefore inﬂict
much weaker host immune responses. We have previously shown that this type of
vector can be used to deliver CFTR gene to lungs of CF knockout mice and protect
the mice from acute bacterial infection. Here we showed that aerosol delivery of
the vector using an Aeroprobe catheter under ﬂexible bronchoscopic guidance was
well-tolerated by all subjects. A robust level of reporter expression was detected.
Interestingly, many submucosal gland cells, the major CFTR-expressing cells in the
airway, were transduced. There was no change in lung function observed based on
the measurements performed before and 30 minutes after the vector delivery. To
examine whether this method can be used for CFTR delivery, we aerosolized a
HD-AD-CFTR vector into pig lungs at different dosages. We have observed dose-
dependent and efﬁcient transgenic CFTR expression in the pigs that received vector
delivery. These results suggest that highly efﬁcient delivery of HD-Ad vectors to
the airway of large animals can be achieved and will provide important insights
into the design of clinical studies for CF lung gene therapy.
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Stem cells may be beneﬁcial for regenerating injured airway epithelium in cystic
ﬁbrosis (CF) lung disease. We evaluated human amniotic mesenchymal stem cells
(hAMSCs) obtained from end term placentae for their ability to differentiate in
vitro in airway epithelium and correct the CF phenotype. Real-time PCR showed
that hAMSCs expressed at low levels CFTR mRNA and g but not a and b
subunits of ENaC. Cytoﬂuorimetric analysis of cocultures of hAMSCs with F508del
homozygous CFBE41o cells seeded at different ratios onto semi-permeable ﬁlters
demonstrated that at least 50−80% of hAMSCs acquired a detectable CFTR expres-
sion on the apical membrane above the background. Confocal microscopy showed
that CFTR was highly expressed on the apical membrane of hAMSCs. Fluorimetric
measure of ion chloride efﬂux allowed to detect an increased function of the CFTR
channel in cocultures as compared with CFBE41o− cells and hAMSCs alone.
Amiloride-dependent ﬂuid absorption decreased when CFBE41o− were cocultured
with hAMSCs respect to CFBE41o− cells alone. Overall, these data show that
hAMSCs are capable to resume some pathological features of CF airway epithelial
cells, although the cellular and molecular mechanisms have to be deciphered.
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The folding and misfolding mechanism of multidomain proteins remains poorly un-
derstood. Although thermodynamic instability of the ﬁrst nucleotide binding domain
(NBD1) of DF508 CFTR partly accounts for the mutant channel degradation in the
endoplasmic reticulum and is considered as a drug target in cystic ﬁbrosis, the link
between NBD1 and CFTR misfolding remains unclear. Here, we show that DF508
further compromises the marginally stable isolated NBD1 thermodynamically and
kinetically. Although introduction of NBD1 stabilizing second site mutations was
sufﬁcient to increase the wild-type CFTR folding efﬁciency, restoring the DF508
NBD1 energetics failed to correct the DF508 CFTR biogenesis. Instead, second
site mutations that stabilized both DF508-NBD1 energetic and the NBD1-MSD2
(membrane-spanning domain 2) interface interactions are required for wild-type
like folding, processing, and transport function, suggesting a synergistic role of
NBD1 energetics and topology in CFTR-coupled domain assembly. Identiﬁcation
of distinct structural deﬁciencies may explain the limited success of DF508 CFTR
corrector molecules and suggests structure-based combination corrector therapies.
These results may also serve as a framework for understanding the mechanism of
interface mutation in multidomain membrane proteins.
